Share on StockTwits

Epizyme (NASDAQ:EPZM) major shareholder Bay City Capital Llc sold 200,000 shares of the stock on the open market in a transaction that occurred on Tuesday, August 26th. The stock was sold at an average price of $35.14, for a total value of $7,028,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Shares of Epizyme (NASDAQ:EPZM) traded down 2.93% on Thursday, hitting $34.18. The stock had a trading volume of 189,273 shares. Epizyme has a 1-year low of $18.10 and a 1-year high of $42.71. The stock has a 50-day moving average of $32.62 and a 200-day moving average of $27.4. The company’s market cap is $1.148 billion.

Epizyme (NASDAQ:EPZM) last released its earnings data on Wednesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.10. The company had revenue of $9.50 million for the quarter, compared to the consensus estimate of $7.59 million. Analysts expect that Epizyme will post $-1.62 EPS for the current fiscal year.

A number of analysts have recently weighed in on EPZM shares. Analysts at HC Wainwright raised their price target on shares of Epizyme from $40.00 to $45.00 in a research note on Wednesday, August 13th. They now have a “buy” rating on the stock. Separately, analysts at Zacks downgraded shares of Epizyme from an “outperform” rating to a “neutral” rating in a research note on Thursday, August 7th. They now have a $36.80 price target on the stock. Finally, analysts at Wainwright initiated coverage on shares of Epizyme in a research note on Tuesday, July 15th. They set a “buy” rating and a $40.00 price target on the stock.

Epizyme, Inc is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers.

Receive News & Ratings for Epizyme Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.